CURC & ARUF | Professor Linhui Wang: Addressing Complications in Retroperitoneal Surgery and Looking Ahead to the Future of Domestic Surgical Robots

CURC & ARUF | Professor Linhui Wang: Addressing Complications in Retroperitoneal Surgery and Looking Ahead to the Future of Domestic Surgical Robots

At this year’s CURC & ARUF Congress, Professor Linhui Wang from the First Affiliated Hospital of the Naval Medical University (Shanghai Changhai Hospital) served as Executive Chair of the meeting. During the Master Lecture session, he delivered a systematic analysis of the causes underlying postoperative abdominal wall bulging following retroperitoneal laparoscopic surgery. The congress also featured extensive live surgical demonstrations and dedicated sessions focused on the clinical application of domestically developed surgical robotic systems. In light of these key topics, Oncology Frontier invited Professor Wang for an in-depth interview.
CUDA Yanqi Lake Conference | Professor Ninghan Feng: Multidisciplinary Integration Empowering the Management of Complex Urologic Tumors — The Practice and Future of the MDT Model

CUDA Yanqi Lake Conference | Professor Ninghan Feng: Multidisciplinary Integration Empowering the Management of Complex Urologic Tumors — The Practice and Future of the MDT Model

As oncology treatment paradigms continue to evolve, the multidisciplinary team (MDT) approach has become a cornerstone of modern cancer care, particularly for the management of complex malignancies. In the field of urologic oncology, MDT care integrates expertise from surgery, medical oncology, radiation oncology, imaging, pathology, and other specialties to provide individualized, full-spectrum treatment strategies that significantly improve patient outcomes.
CUDA Yanqi Lake Conference | Exclusive Interview with Professor Hong Liao: In the Era of Precision Therapy for Prostate Cancer, How Do We Move from “Experience-Driven” to “Evidence-Driven” Care?

CUDA Yanqi Lake Conference | Exclusive Interview with Professor Hong Liao: In the Era of Precision Therapy for Prostate Cancer, How Do We Move from “Experience-Driven” to “Evidence-Driven” Care?

Prostate cancer is the second most commonly diagnosed malignancy and the fifth leading cause of cancer-related death among men worldwide. In recent years, with the rapid advancement of molecular biology technologies and the emergence of novel therapeutic agents, prostate cancer management has officially entered the era of precision medicine. Clinical decision-making is undergoing a profound transformation—from the traditional “one-size-fits-all” approach to individualized treatment strategies guided by precise staging and molecular profiling.
CUDA Yanqi Lake Conference | From Personal Mastery to Broader Impact: The Growth and Legacy of a Urologic Surgeon

CUDA Yanqi Lake Conference | From Personal Mastery to Broader Impact: The Growth and Legacy of a Urologic Surgeon

The 2026 Yanqi Lake Academic Conference for Urologists was successfully held in Beijing. During the meeting, Conference Chair Professor Nianzeng Xing, Vice President of the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences, shared his personal journey during the special session “From a Skilled Commander to a Strategic Leader.” He reflected on his transformation from a surgeon striving for technical perfection in the operating room to a discipline leader committed to cultivating teams and advancing the field as a whole.
AOT 2026 | Professor Matthias Stelljes: Therapeutic Pathways and Key Decision-Making Considerations in Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

AOT 2026 | Professor Matthias Stelljes: Therapeutic Pathways and Key Decision-Making Considerations in Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care and hosted by the National Clinical Research Center for Hematologic Diseases and the Peking University Institute of Hematology, this year’s conference centered on the theme “The Art of Transplantation.” The meeting brought together leading hematology experts from around the world to discuss cutting-edge innovations and future directions in hematopoietic stem cell transplantation.
AOT 2026 | Professor Donal P. McLornan: Challenges, Strategies, and Future Directions for Hematopoietic Stem Cell Transplantation in MDS/MPN

AOT 2026 | Professor Donal P. McLornan: Challenges, Strategies, and Future Directions for Hematopoietic Stem Cell Transplantation in MDS/MPN

To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care and hosted by the National Clinical Research Center for Hematologic Diseases and the Peking University Institute of Hematology, this year’s conference centered on the theme “The Art of Transplantation.” The meeting brought together leading hematology experts from around the world to discuss cutting-edge innovations and emerging trends in hematopoietic stem cell transplantation.
CSCO Guideline Preview | Professor Cuijian Zhang: Six Years of Evolution in the Urothelial Carcinoma Guidelines as ADCs and Novel Therapies Further Reshape Clinical Practice

CSCO Guideline Preview | Professor Cuijian Zhang: Six Years of Evolution in the Urothelial Carcinoma Guidelines as ADCs and Novel Therapies Further Reshape Clinical Practice

With the continuous emergence of novel therapies and landmark clinical evidence, the treatment landscape of urothelial carcinoma is undergoing profound transformation. Ahead of the 2026 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference, Oncology Frontier – UroStream presents a special series of expert previews on major genitourinary oncology guidelines. In this issue, Professor Cuijian Zhang from Peking University First Hospital, Secretary of the CSCO Urothelial Carcinoma Expert Committee, discusses the evolution of the CSCO urothelial carcinoma guidelines, highlights potential updates in the upcoming edition, and shares insights into the clinical significance of emerging evidence and future directions in the field. His perspectives offer clinicians an early look at evolving treatment paradigms aimed at improving outcomes for Chinese patients.
Old Drug, New Use! Professor Kan Gong’s Team from Peking University First Hospital Collaborates with International Experts to Propose a Novel Combination Strategy for Renal Cell Carcinoma

Old Drug, New Use! Professor Kan Gong’s Team from Peking University First Hospital Collaborates with International Experts to Propose a Novel Combination Strategy for Renal Cell Carcinoma

Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, among which approximately 75% are clear cell renal cell carcinoma (ccRCC). Loss of the VHL gene is the key molecular event driving this disease. VHL inactivation places tumor cells in a persistent state of “pseudohypoxia,” continuously activating HIF-2α-centered oncogenic transcriptional programs that promote angiogenesis, cell proliferation, and metabolic reprogramming.